Not CRISPR data: the image illustrates antibody quality for visualizing CRISPR experiment results.
Not CRISPR data: the image illustrates antibody quality for visualizing CRISPR experiment results.
ZWINT CRISPR/Cas9 KO Plasmid (h): sc-405718
- Target species: human
- 20 µg of transfection-ready, purified plasmid DNA; Suitable for up to 20 transfections
- ZWINT CRISPR/Cas9 Knockout (KO) Plasmid (h) is a pool of plasmids, each encoding Cas9 nuclease and a target-specific 20 nt guide RNA (gRNA) designed for maximum knockout efficiency using sequences derived from the GeCKO v2 library
- gRNA sequences direct Cas9 to induce site-specific double-strand breaks (DSBs) in the ZWINT genomic locus, resulting in gene knockout through non-homologous end joining (NHEJ)
- The puromycin resistance and RFP genes are flanked by LoxP sites, enabling removal of selection markers via Cre recombinase (Cre Vector: sc-418923) after establishing stable knockout cell lines
- Following transfection, gene knockout efficiency can be assayed by WB, IF or IHC using antibody: ZWINT Antibody (G-12): sc-166730
Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
ZWINT CRISPR/Cas9 KO Plasmid (h) | sc-405718 | 20 µg | $397.00 |
Overview
ZWINT (ZW10 interacting kinetochore protein) is a conserved component of the outer kinetochore that supports stable microtubule attachment and accurate chromosome segregation during mitosis. It interacts with the ZW10/RZZ complex and contributes to spindle assembly checkpoint signaling, coupling kinetochore-microtubule dynamics to cell-cycle progression. Altered ZWINT expression or function has been associated with chromosomal instability and proliferative phenotypes observed across multiple cancer contexts, making it relevant for studies of aneuploidy and genome maintenance. As a mitotic regulator, ZWINT is frequently examined in pathways linking checkpoint control, kinetochore architecture, and mitotic stress responses.
ZWINT CRISPR/Cas9 KO Plasmid (h) is a pool of plasmids designed for targeted disruption of the ZWINT gene in human cell lines. Each plasmid co-expresses a unique single guide RNA (sgRNA) targeting a distinct site within the ZWINT together with the Streptococcus pyogenes Cas9 nuclease. The plasmids also encode GFP, allowing fluorescent identification and enrichment of successfully transfected cells by fluorescence microscopy or flow cytometry.
The multi-guide design increases the likelihood of generating insertions or deletions (indels) that disrupt the ZWINT open reading frame following Cas9-mediated double-strand break formation. DNA breaks introduced by the CRISPR/Cas9 system are repaired through endogenous non-homologous end joining (NHEJ) pathways, frequently resulting in frameshift mutations that abolish ZWINT protein expression.
This CRISPR knockout system enables efficient generation of ZWINT-deficient cell models for investigation of ZWINT signaling, functional genomics studies, cancer biology research, and evaluation of therapeutic responses in human cell lines.
Key Features
- sgRNAs targeting ZWINT exon(s) critical for ZWINT function
- Co-expression of SpCas9 and sgRNA from a single plasmid for simplified delivery
- GFP reporter for identification of transfected cells
- Pool of plasmids targeting multiple ZWINT genomic sites to improve knockout efficiency
- Compatible with delivery by transfection
Design Variants
CRISPRs +/- HDRs
- gRNAs encoded by ZWINT CRISPR/Cas9 KO Plasmid (h) and ZWINT CRISPR/Cas9 KO Plasmid (h2) target distinct sites within the ZWINT locus. One or both targeting designs may be available. See Related Products for availability.
- HDR donor constructs encoded by ZWINT HDR Plasmid (h) and ZWINT HDR Plasmid (h2) contain a puromycin resistance cassette and an RFP reporter flanked by ZWINT homology arms to support homology-directed repair at defined ZWINT target sites corresponding to the CRISPR/Cas9 KO designs. HDR donor availability may vary. See Related Products for availability.
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.